Clinical trialNCT07674745Not, yet, recruitingPhase 2Interventional

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

SponsorUniversity of Alabama at BirminghamEnrollment52Idiopathic Pulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Steven R Duncan, MD
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Steven R Duncan, MD
Loyola University
Chicago, Illinois, United States
Daniel Dilling, MD
Northwestern University
Chicago, Illinois, United States
Anthony Esposito, MD
University of Kansas
Kansas City, Kansas, United States
Mark Hamblin, MD
University of North Carolina
Chapel Hill, North Carolina, United States
Sean Callahan, MD
Temple University
Philadelphia, Pennsylvania, United States
Gerald R Criner, MD
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Ross Summer, MD
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Dan Kass, MD
University of Utah
Salt Lake City, Utah, United States
Mary Beth Scholand, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intravenous immunoglobulinRituximab →Treatment as Usual

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Oct 2026
Primary completion: 30 Sept 2030
Completion: 31 Mar 2031
Last update posted: 1 Jul 2026
Registered enrollment: 52
Registry id: NCT07674745

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.